GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Epizyme Inc (NAS:EPZM) » Definitions » Gross Margin %

Epizyme (Epizyme) Gross Margin % : 81.11% (As of Jun. 2022)


View and export this data going back to 2013. Start your Free Trial

What is Epizyme Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Epizyme's Gross Profit for the three months ended in Jun. 2022 was $22.33 Mil. Epizyme's Revenue for the three months ended in Jun. 2022 was $27.53 Mil. Therefore, Epizyme's Gross Margin % for the quarter that ended in Jun. 2022 was 81.11%.


The historical rank and industry rank for Epizyme's Gross Margin % or its related term are showing as below:

EPZM' s Gross Margin % Range Over the Past 10 Years
Min: 67.85   Med: 69.9   Max: 75.57
Current: 75.57


During the past 11 years, the highest Gross Margin % of Epizyme was 75.57%. The lowest was 67.85%. And the median was 69.90%.

EPZM's Gross Margin % is not ranked
in the Biotechnology industry.
Industry Median: 59.44 vs EPZM: 75.57

Epizyme had a gross margin of 81.11% for the quarter that ended in Jun. 2022 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Epizyme was 0.00% per year.


Epizyme Gross Margin % Historical Data

The historical data trend for Epizyme's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Epizyme Gross Margin % Chart

Epizyme Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 67.85 71.95

Epizyme Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 80.78 61.57 72.78 70.10 81.11

Competitive Comparison of Epizyme's Gross Margin %

For the Biotechnology subindustry, Epizyme's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Epizyme's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Epizyme's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Epizyme's Gross Margin % falls into.



Epizyme Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Epizyme's Gross Margin for the fiscal year that ended in Dec. 2021 is calculated as

Gross Margin % (A: Dec. 2021 )=Gross Profit (A: Dec. 2021 ) / Revenue (A: Dec. 2021 )
=26.9 / 37.427
=(Revenue - Cost of Goods Sold) / Revenue
=(37.427 - 10.498) / 37.427
=71.95 %

Epizyme's Gross Margin for the quarter that ended in Jun. 2022 is calculated as


Gross Margin % (Q: Jun. 2022 )=Gross Profit (Q: Jun. 2022 ) / Revenue (Q: Jun. 2022 )
=22.3 / 27.528
=(Revenue - Cost of Goods Sold) / Revenue
=(27.528 - 5.2) / 27.528
=81.11 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Epizyme  (NAS:EPZM) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Epizyme had a gross margin of 81.11% for the quarter that ended in Jun. 2022 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Epizyme Gross Margin % Related Terms

Thank you for viewing the detailed overview of Epizyme's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Epizyme (Epizyme) Business Description

Traded in Other Exchanges
N/A
Address
400 Technology Square, 4th Floor, Cambridge, MA, USA, 02139
Epizyme Inc is a clinical-stage biopharmaceutical company that is committed to rewriting treatment for cancer and other serious diseases through discovering, developing, and commercializing novel epigenetic medicines. Its product candidates include one approved product, TAZVERIK (tazemetostat), an inhibitor of the EZH2. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias and PRMT5 inhibitor.
Executives
Jeffery Kutok officer: Chief Scientific Officer 784 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Jerald Korn officer: Chief Operating Officer 128 GORDON RD, NEWTON MA 02468
Joseph Beaulieu officer: Corporate Controller C/O EPIZYME, INC. 400 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Shefali Agarwal officer: Chief Medical Officer C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Royalty Pharma Investments 2019 Icav director, 10 percent owner C/O RP MANAGEMENT, LLC 100 E. 59TH ST., 33RD FLOOR NEW YORK NY 10022
Pablo G. Legorreta director 110 E 59TH STREET, SUITE 3300, NEW YORK NY 10022
Carol Stuckley director C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Roy A Beveridge, director 500 W MAIN ST, LOUISVILLE KY 40202
David M Mott director 1119 ST. PAUL STREET, BALTIMORE MD 21202
Robert B Bazemore director, officer: President & CEO 33 HAYDEN AVE, LEXINGTON MA 02421
Matthew Ros officer: Chief Operating Officer C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Paolo Tombesi officer: Chief Financial Officer 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Victoria Vakiener officer: Chief Commercial Officer C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Carl Goldfischer director 161 WEST 61ST STREET, NEW YORK NY 10022
Rp Management, Llc director 110 EAST 59TH STREET SUITE 3300 NEW YORK NY 10022

Epizyme (Epizyme) Headlines

From GuruFocus

Epizyme to Participate in Upcoming Healthcare Conferences in March

By Business Wire Business Wire 03-02-2022

Epizyme To Participate in H.C. Wainwright Global Investment Conference

By Business Wire Business Wire 05-17-2022

Palo Alto Investors LP Buys 2, Sells 3 in 3rd Quarter

By GuruFocus Research GuruFocus Editor 11-15-2022

Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology

By Business Wire Business Wire 06-27-2022